Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade
- Study type
- Review article
- Design
- Review article (no quantitative pooled analysis in the abstract)
- Source
- Int. J. Mol. Sci. · 2026
In plain words
Personalised mRNA vaccines are made from the specific mutations in each patient's own tumour, to train the immune system to recognise and attack cancer cells. This article reviews how combining these vaccines with immune checkpoint inhibitor drugs (such as PD-1/PD-L1 inhibitors) may help make the immune response stronger and longer-lasting. The evidence reviewed concerns melanoma, non-small cell lung cancer and pancreatic cancer. This is a review article, and treatment decisions should be discussed with the treating doctor.
Study population
This article is a review and did not enrol a specific patient population. The evidence reviewed concerns melanoma, non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
Endpoints
The abstract reports no primary or secondary endpoints, as this is a review. The themes covered are molecular neoantigen selection and mRNA vaccine design, vaccine-driven remodelling of antitumour T-cell immunity, and clinical integration with PD-1/PD-L1 blockade.
Safety and side effects
The abstract does not report safety or adverse event data (such as grade 3 or higher events). For safety information, the full text and the primary trial reports should be consulted.
Clinical significance and place in guidelines
This article is a review and does not directly change clinical practice. The abstract emphasises the importance of biomarker-based patient selection and future combination strategies. Regulatory approval status and guideline recommendations for intismeran autogene and autogene cevumeran are not mentioned in the abstract and should be checked separately in reliable sources.
Limitations
The abstract does not state the review's limitations. As a review, it presents no new primary data, and some of the trials reviewed are still ongoing. The search method and study selection criteria are not stated in the abstract.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.